Open Access

Stanniocalcin 1 is a prognostic biomarker in glioma

  • Authors:
    • Weijian Luo
    • Dong Chen
    • Hao Wang
    • Jiliang Hu
  • View Affiliations

  • Published online on: July 1, 2020     https://doi.org/10.3892/ol.2020.11792
  • Pages: 2248-2256
  • Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Malignant gliomas are the most common type of primary malignancy of the central nervous system with a poor prognosis. Stanniocalcin 1 (STC1) is closely associated with tumor genesis and development. However, its role in the development and progression of glioma is poorly understood. In silico analysis, The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), Rembrandt and GSE16011 datasets were used to assess the expression levels of STC1 in non‑tumor brain tissues and gliomas. Moreover, reverse transcription‑quantitative PCR and immunohistochemistry were used to detect STC1 expression in tumor tissues collected in the Department of Neurosurgery of Shenzhen People's Hospital (Shenzhen, China). The association between STC1 expression and different molecular pathological features was analyzed in four public datasets, as well as via Kaplan‑Meier analysis. Furthermore, normalized mRNA expression in TCGA was used to perform Gene Ontology analysis. It was revealed that STC1 expression was significantly elevated in glioma tissues compared with the non‑tumor brain tissues, both in silico analysis and via cohort validation. According to TCGA, CGGA, Rembrandt and GSE16011 datasets, it was identified that STC1 expression was increased in high grade glioma compared with low grade glioma. In addition, the results indicated STC1 expression was enriched in the isocitrate dehydrogenase (IDH) wild‑type and mesenchymal subtype in TCGA, GSE16011 and Rembrandt datasets. Moreover, it was demonstrated that patients with higher STC1 expression exhibited shorter overall survival times compared with those with lower STC1 expression using Kaplan‑Meier analysis, according to both the public datasets and validation cohort. Furthermore, the results of the Gene Ontology analysis demonstrated that STC1 was primarily involved in the reorganization of extracellular matrix and was significantly correlated with invasive‑related proteins. Therefore, the present results indicate that STC1 was upregulated in glioma tissues and may represent a prognostic biomarker in patients with glioma.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Luo W, Chen D, Wang H and Hu J: Stanniocalcin 1 is a prognostic biomarker in glioma. Oncol Lett 20: 2248-2256, 2020
APA
Luo, W., Chen, D., Wang, H., & Hu, J. (2020). Stanniocalcin 1 is a prognostic biomarker in glioma. Oncology Letters, 20, 2248-2256. https://doi.org/10.3892/ol.2020.11792
MLA
Luo, W., Chen, D., Wang, H., Hu, J."Stanniocalcin 1 is a prognostic biomarker in glioma". Oncology Letters 20.3 (2020): 2248-2256.
Chicago
Luo, W., Chen, D., Wang, H., Hu, J."Stanniocalcin 1 is a prognostic biomarker in glioma". Oncology Letters 20, no. 3 (2020): 2248-2256. https://doi.org/10.3892/ol.2020.11792